DiaMedica Therapeutics Inc. (DMAC) vs ARS Pharmaceuticals, Inc. (SPRY)
A side-by-side comparison of DiaMedica Therapeutics Inc. and ARS Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
DMAC
DiaMedica Therapeutics Inc.
$8.33HealthcareDelayed quote: Oct 6, 2026, 3:15 PM EDT
SPRY
ARS Pharmaceuticals, Inc.
$4.29HealthcareDelayed quote: Oct 6, 2026, 3:10 PM EDT
Total return — DMAC vs SPRY
growth of $100 · dividends reinvested · last 6yDMAC +63.8% (+8.6%/yr)SPRY -82.8% (-25.5%/yr)DMAC compounded faster over this window
Log scale — wide-divergence pair
DMAC SPRY
DMAC vs SPRY: by the numbers
- •DMAC is the larger company ($449M vs $426M market cap).
- •Both run net losses; DMAC's is the smaller (0.00% vs -184.24% net margin).
Metrics side by side
Valuation
| Metric | DMAC | SPRY |
|---|---|---|
| P/S ratio | N/A | 3.64 |
| P/B ratio | 11.71 | 34.01 |
Profitability
| Metric | DMAC | SPRY |
|---|---|---|
| Gross margin | 0.00% | 73.89% |
| Operating margin | 0.00% | -212.92% |
| Net margin | 0.00% | -184.24% |
| ROE | -97.92% | -1721.80% |
| ROIC | -100.87% | -114.65% |
Growth (annualized)
| Metric | DMAC | SPRY |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 36.43% |
| Total return CAGR (5Y) | 16.41% | -16.35% |
Frequently asked
- How have DMAC and SPRY total returns compared?
- Over the past 5 years, DMAC delivered 16.41% and SPRY delivered -16.35% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
DiaMedica Therapeutics ROEARS Pharmaceuticals ROEDiaMedica Therapeutics operating marginARS Pharmaceuticals operating marginDiaMedica Therapeutics revenue growthARS Pharmaceuticals revenue growthDiaMedica Therapeutics free cash flowARS Pharmaceuticals free cash flow
DiaMedica Therapeutics & ARS Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.